Navigation Links
Neuropathy Patients, Doctors and Medical Professionals Rally in Sacramento to Demand Access to Lifesaving Medical Treatments
Date:6/25/2009

California Assemblymember Mary Hayashi Calls on California Congressional Delegation to Remember Needs of Neuropathy Patients at 3rd Annual "Neuropathy Action Awareness Day"

SACRAMENTO, Calif., June 25 /PRNewswire/ -- As President Obama continues his push for national health care reform, more than 300 neuropathy patients, physicians and medical professionals gathered in Sacramento today to call on Congress to restore access to life-sustaining and lifesaving treatments for neuropathy patients. At a press conference kicking off the third annual "Neuropathy Action Awareness Day," California Assemblymember Mary Hayashi and those in attendance signed a petition encouraging the California Members of Congress to remember the needs of neuropathy patients while working on federal health care reform legislation.

"Neuropathy patients and advocates in California spoke with one voice today to demand access to the lifesaving treatments we need, and to help ensure that Congress protects neuropathy patients as it continues the national health care reform debate," said Michelle Vogel, Executive Director of the Alliance for Plasma Therapies. "As President Obama and Congress look for ways to cut health care spending, they must also restore access to critical therapies such as IVIG (intravenous immune globulin) which is used to treat patients suffering from neuropathy, multiple sclerosis, myositis and pemphigus, among other conditions."

Neuropathy Action Awareness Day, sponsored by the Neuropathy Action Foundation (NAF) and the Alliance for Plasma Therapies (APT), gathered patients, physicians and medical professionals and representatives from other organizations including The Neuropathy Association, Foundation for Peripheral Neuropathy and International Pemphigus and Pemphigoid Foundation to learn about neuropathy and to promote awareness of the disease. Patients and patient advocates in attendance signed a petition, to be delivered to the California Congressional delegation, which stated:

        We, the undersigned, respectfully ask the Members of Congress from the
        State of California to co-sponsor H.R. 2002 and S. 701, the Medicare
        Patient IVIG Access Act of 2009, which restores access in all sites of
        care to intravenous immune globulin (IVIG) to patients who rely on
        this lifesaving therapy.  We further ask our Members of Congress to
        remember, while debating healthcare reform, that all patients,
        especially those with rare diseases, need access to all therapies
        prescribed appropriately by their physician and that because every
        patient is unique, personalized medicine must play a role in
        diagnosing and treating patients with all diseases.

"Every time my neurologist orders a treatment, managed care denies the request, and each time I have to file an appeal to receive the treatment that my doctor thinks is best," said Stacey Westurlund, a 31-year-old social worker and neuropathy patient from Lodi, CA, who spoke at the press conference today. "I have to employ my skills as a social worker to become my own advocate - researching available treatment options, partnering with my doctors, and appealing managed care and insurance company decisions."

Westurlund, who signed the petition to Members of Congress after Assemblymember Hayashi, was misdiagnosed for a year before being diagnosed with a form of polyneuropathy. Stacey benefits from regular treatments of IVIG at home through Medicare, but because her painful condition keeps her from driving, she was forced to fight health insurers for months until she got coverage to receive her treatments at her home.

"The last major health care reform legislation passed by Congress decreased Medicare reimbursements for neuropathy patients and increased obstacles to getting timely and effective treatment," said Michelle Vogel. "In addition to restoring access to treatment for all Americans, Congress should enable physicians, not health insurers, to determine what is best for patients and what constitutes medically necessary care."

About the Neuropathy Action Foundation

The Neuropathy Action Foundation (NAF) is dedicated to ensuring neuropathy patients obtain the necessary resources, information and tools to access individualized treatment to improve their quality of life. The NAF increases awareness among physicians, appropriate institutions, the general public and public policy officials that neuropathy can potentially be a serious, widespread and disabling condition, which may be treatable when appropriate medical care is provided.

www.neuropathyaction.org

About the Alliance for Plasma Therapies

The Alliance for Plasma Therapies is a national non-profit organization established to provide a unified, powerful voice of patient organizations, healthcare providers and industry leaders to educate about the diseases that rely on plasma derived therapies and advocate for fair access to plasma therapies for patients who benefit from their lifesaving effects.

www.plasmaalliance.org


'/>"/>
SOURCE Alliance for Plasma Therapies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
2. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
3. Current and Emerging Therapies Have No Advantage Over Pfizers Lyrica in Their Effect on Patients Quality of Life in the Treatment of Diabetic Neuropathy
4. The Neuropathy Association Featured on NBCs Today Show as Part of National Neuropathy Week
5. The cause of all hereditary sensory and autonomic neuropathy type II cases has been established
6. The Neuropathy Associations Scientific Research Grants Focus: Autoimmune and Chemotherapy-Induced Neuropathies
7. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
8. Doctors Issue New Neuropathy Test Guidelines
9. ReBuilder Medical (RBRM) Neuropathy Market Doubles to $5 Billion
10. "Electric Socks" for Neuropathy??
11. Gene Therapy Improves Diabetic Neuropathy in Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... The ... candidates for the Board of Commissioners. Individuals interested in volunteer board service are ... diversity of clinical practice settings and across allied health to contribute to its ...
(Date:2/11/2016)... SURPRISE, ARIZ. (PRWEB) , ... February 11, 2016 , ... ... kids,” a group of men, 60 and older, who gather once a year to ... , Besides a love for the game, the more than 50 players who competed ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. ... Infusion Therapy Standards of Practice, to include vascular visualization as a standard practice. ... 85% share of the market, facilitates adherence to this standard with its easy ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services ... a new fundraiser in support of a local boy named Barrett, who has been ... bring awareness to, and rally support for, all local families dealing with childhood cancer. ...
(Date:2/11/2016)... ... ... Be Well Medical Group (Be Well) is pleased to announce the ... Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group is a concierge practice ... their homes, offices or at the practices’ local office. It is also one of ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 11, 2016 ... of the "Molecular Diagnostics Reports Bundle" ... http://www.researchandmarkets.com/research/rp4pg8/molecular ) has announced the addition ... report to their offering. --> ... has announced the addition of the ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
(Date:2/10/2016)... -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... quarter and full year ended December 31, 2015. ... a transformational year for Vanda with the continued growth ... approval of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, ... to our U.S. product portfolio builds on this success ...
Breaking Medicine Technology: